Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova VS, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner C. Novak U, et al. Among authors: schar s. EClinicalMedicine. 2023 Sep 22;64:102221. doi: 10.1016/j.eclinm.2023.102221. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37781158 Free PMC article.
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.
Ceriani L, Gritti G, Cascione L, Pirosa MC, Polino A, Ruberto T, Stathis A, Bruno A, Moccia AA, Giovanella L, Hayoz S, Schär S, Dirnhofer S, Rambaldi A, Martinelli G, Mamot C, Zucca E. Ceriani L, et al. Among authors: schar s. Blood Adv. 2020 Mar 24;4(6):1082-1092. doi: 10.1182/bloodadvances.2019001201. Blood Adv. 2020. PMID: 32196557 Free PMC article.
Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).
Moccia AA, Schär S, Hayoz S, Pirosa MC, Taverna C, Novak U, Kimby E, Ghielmini M, Zucca E. Moccia AA, et al. Among authors: schar s. Br J Haematol. 2021 Mar;192(6):1031-1034. doi: 10.1111/bjh.17045. Epub 2020 Aug 17. Br J Haematol. 2021. PMID: 32805081 Free article. Clinical Trial.
Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
Zucca E, Cascione L, Ruberto T, Facchinelli D, Schär S, Hayoz S, Dirnhofer S, Giovanella L, Bargetzi M, Mamot C, Ceriani L. Zucca E, et al. Among authors: schar s. Hematol Oncol. 2020 Dec;38(5):715-725. doi: 10.1002/hon.2805. Epub 2020 Oct 4. Hematol Oncol. 2020. PMID: 32947651
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
Moccia AA, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Raats J, Rauch D, Vorobiof DA, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Zucca E. Moccia AA, et al. Among authors: schar s. Blood Adv. 2020 Dec 8;4(23):5951-5957. doi: 10.1182/bloodadvances.2020002858. Blood Adv. 2020. PMID: 33275769 Free PMC article. Clinical Trial.
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.
Ceriani L, Milan L, Cascione L, Gritti G, Dalmasso F, Esposito F, Pirosa MC, Schär S, Bruno A, Dirnhofer S, Giovanella L, Hayoz S, Mamot C, Rambaldi A, Chauvie S, Zucca E. Ceriani L, et al. Among authors: schar s. Hematol Oncol. 2022 Feb;40(1):11-21. doi: 10.1002/hon.2935. Epub 2021 Oct 29. Hematol Oncol. 2022. PMID: 34714558
Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.
Genta S, Ghilardi G, Cascione L, Juskevicius D, Tzankov A, Schär S, Milan L, Pirosa MC, Esposito F, Ruberto T, Giovanella L, Hayoz S, Mamot C, Dirnhofer S, Zucca E, Ceriani L. Genta S, et al. Among authors: schar s. Cancers (Basel). 2022 Feb 17;14(4):1018. doi: 10.3390/cancers14041018. Cancers (Basel). 2022. PMID: 35205765 Free PMC article.
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle DL, Hess D, Moccia AA, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. Stathis A, et al. Among authors: schar s. Blood Adv. 2022 Jul 12;6(13):3911-3920. doi: 10.1182/bloodadvances.2021006520. Blood Adv. 2022. PMID: 35537101 Free PMC article. Clinical Trial.
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.
Schmid S, Mauti LA, Friedlaender A, Blum V, Rothschild SI, Bouchaab H, Frösch P, Britschgi C, König D, Wannesson L, Janthur WD, Schär S, Demmer I, Addeo A, Jochum W, Früh M. Schmid S, et al. Among authors: schar s. Cancer Immunol Immunother. 2020 Aug;69(8):1605-1613. doi: 10.1007/s00262-020-02565-0. Epub 2020 Apr 19. Cancer Immunol Immunother. 2020. PMID: 32307579 Free PMC article.
35 results